Have a feature idea you'd love to see implemented?
Let us know!
ADPT Adaptive Biotechnologies Corp
Price (delayed)
$6.39
Market cap
$943.03M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.34
Enterprise value
$1.13B
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the
Highlights
The company's net income rose by 9% QoQ
ADPT's EPS is up by 9% since the previous quarter
The gross profit has grown by 12% since the previous quarter but it has declined by 3.3% year-on-year
ADPT's equity is down by 38% year-on-year and by 7% since the previous quarter
The quick ratio has declined by 24% year-on-year and by 13% since the previous quarter
Key stats
What are the main financial stats of ADPT
Market
Valuations
Earnings
Shares outstanding
147.58M
Market cap
$943.03M
Enterprise value
$1.13B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.21
Price to sales (P/S)
5.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.35
Revenue
$177.28M
Gross profit
$103.63M
Net income
-$195.24M
EBIT
-$183.6M
EBITDA
-$157.99M
Free cash flow
-$114.54M
Per share
Balance sheet
Liquidity
EPS
-$1.34
EPS diluted
-$1.34
Free cash flow per share
-$0.78
Book value per share
$1.52
Revenue per share
$1.2
TBVPS
$2.95
Total assets
$558.51M
Total liabilities
$334.93M
Debt
$224.53M
Equity
$223.77M
Working capital
$220.72M
Debt to equity
1
Current ratio
3.52
Quick ratio
3.28
Net debt/EBITDA
-1.16
Margins
Efficiency
Dividend
EBITDA margin
-89.1%
Gross margin
58.5%
Net margin
-110.1%
Operating margin
-112.7%
Return on assets
-32.2%
Return on equity
-74.5%
Return on invested capital
-32.7%
Return on capital employed
-39%
Return on sales
-103.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADPT stock price
How has the Adaptive Biotechnologies stock price performed over time
Intraday
6.5%
1 week
1.43%
1 month
44.57%
1 year
34.81%
YTD
30.41%
QTD
24.8%
Financial performance
How have Adaptive Biotechnologies's revenue and profit performed over time
Revenue
$177.28M
Gross profit
$103.63M
Operating income
-$199.78M
Net income
-$195.24M
Gross margin
58.5%
Net margin
-110.1%
Adaptive Biotechnologies's operating margin has increased by 13% QoQ but it has decreased by 3.8% YoY
ADPT's net margin is up by 13% since the previous quarter
The gross profit has grown by 12% since the previous quarter but it has declined by 3.3% year-on-year
The company's net income rose by 9% QoQ
Growth
What is Adaptive Biotechnologies's growth rate over time
Valuation
What is Adaptive Biotechnologies stock price valuation
P/E
N/A
P/B
4.21
P/S
5.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.35
ADPT's EPS is up by 9% since the previous quarter
ADPT's P/B is 75% above its last 4 quarters average of 2.4 but 17% below its 5-year quarterly average of 5.1
ADPT's equity is down by 38% year-on-year and by 7% since the previous quarter
ADPT's price to sales (P/S) is 78% lower than its 5-year quarterly average of 24.5 but 48% higher than its last 4 quarters average of 3.6
The revenue has grown by 5% from the previous quarter
Efficiency
How efficient is Adaptive Biotechnologies business performance
The ROE has shrunk by 57% YoY and by 3.5% QoQ
Adaptive Biotechnologies's ROA has decreased by 29% YoY but it has increased by 2.4% from the previous quarter
The ROIC has contracted by 25% YoY but it has grown by 4.4% from the previous quarter
ADPT's return on sales is up by 13% since the previous quarter but it is down by 2.6% year-on-year
Dividends
What is ADPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADPT.
Financial health
How did Adaptive Biotechnologies financials performed over time
The total assets is 67% more than the total liabilities
The current ratio has contracted by 25% YoY and by 12% from the previous quarter
The quick ratio has declined by 24% year-on-year and by 13% since the previous quarter
ADPT's debt to equity has surged by 56% year-on-year and by 6% since the previous quarter
ADPT's equity is down by 38% year-on-year and by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.